Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Obrist

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Cancer Research|March 1, 1983
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvumR C Bast, J S Berek, R Obrist, et al.
American Journal of Obstetrics and Gynecology|August 15, 1985
Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvumJ S Berek, R C Knapp, N F Hacker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1993
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled studyK S Buser, R A Joss, D Piquet, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Cancer Research|March 1, 1983
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvumR C Bast, J S Berek, R Obrist, et al.
American Journal of Obstetrics and Gynecology|August 15, 1985
Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvumJ S Berek, R C Knapp, N F Hacker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1993
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled studyK S Buser, R A Joss, D Piquet, et al.
Pageof 7